Shared on23 Oct 25Fair value Increased 1.61%
Analysts have increased their price target for West Pharmaceutical Services by $5 to $321. They cited the company's encouraging earnings call, management's confidence in future estimates, and stable end markets with improving investment sentiment.
Shared on30 Apr 25Fair value Decreased 3.86%
AnalystConsensusTarget has increased revenue growth from 4.5% to 5.3%.
Shared on23 Apr 25Fair value Increased 1.92%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on16 Apr 25Fair value Decreased 0.18%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.73%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.39%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Increased 0.47%
AnalystConsensusTarget has decreased revenue growth from 6.6% to 4.3%, decreased profit margin from 20.7% to 17.9% and decreased future PE multiple from 46.9x to 41.4x.